Third Phase III Success Puts Lexicon/Sanofi's Sotagliflozin On Track For NDA Filing

Intended mainly to provide evidence of a safety advantage compared to existing SGLT2 inhibitors, meeting the net-benefit primary endpoint in the inTandem3 trial puts sotagliflozin in good shape for approval as add-on glycemic-control therapy in type 1 diabetes.